loading
Schlusskurs vom Vortag:
$1.66
Offen:
$1.66
24-Stunden-Volumen:
807.00K
Relative Volume:
0.50
Marktkapitalisierung:
$70.53M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-97.22M
KGV:
-1.1377
EPS:
-1.38
Netto-Cashflow:
$-82.44M
1W Leistung:
+9.03%
1M Leistung:
-17.37%
6M Leistung:
-94.09%
1J Leistung:
-92.77%
1-Tages-Spanne:
Value
$1.56
$1.66
1-Wochen-Bereich:
Value
$1.37
$1.73
52-Wochen-Spanne:
Value
$1.15
$42.20

Cassava Sciences Inc Stock (SAVA) Company Profile

Name
Firmenname
Cassava Sciences Inc
Name
Telefon
512-501-2444
Name
Adresse
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Name
Mitarbeiter
30
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
SAVA's Discussions on Twitter

Vergleichen Sie SAVA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SAVA
Cassava Sciences Inc
1.57 70.53M 0 -97.22M -82.44M -1.38
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-11-26 Herabstufung H.C. Wainwright Buy → Neutral
2024-10-08 Hochstufung H.C. Wainwright Neutral → Buy
2024-07-01 Herabstufung H.C. Wainwright Buy → Neutral
2022-11-16 Herabstufung B. Riley Securities Buy → Neutral
2021-07-15 Herabstufung Cantor Fitzgerald Overweight → Neutral
2021-07-07 Bestätigt Maxim Group Buy
2021-04-27 Eingeleitet B. Riley Securities Buy
2021-02-16 Bestätigt H.C. Wainwright Buy
2020-10-23 Eingeleitet Cantor Fitzgerald Overweight
2020-09-23 Hochstufung H.C. Wainwright Neutral → Buy
2020-05-18 Herabstufung H.C. Wainwright Buy → Neutral
2020-05-15 Herabstufung Maxim Group Buy → Hold
2020-01-10 Bestätigt Maxim Group Buy
Alle ansehen

Cassava Sciences Inc Aktie (SAVA) Neueste Nachrichten

pulisher
Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 22, 2025

Cassava Sciences (SAVA) Announces Leadership Change Amid Future Strategy Plans - GuruFocus

Apr 22, 2025
pulisher
Apr 21, 2025

Cassava Sciences appoints new SVP of Clinical Development By Investing.com - Investing.com South Africa

Apr 21, 2025
pulisher
Apr 21, 2025

Cassava Sciences CMO James Kupiec to Retire - marketscreener.com

Apr 21, 2025
pulisher
Apr 21, 2025

Cassava chief medical officer to retire - Seeking Alpha

Apr 21, 2025
pulisher
Apr 21, 2025

Cassava Sciences Announces Leadership Changes Amid Strategic Shift - TipRanks

Apr 21, 2025
pulisher
Apr 21, 2025

Cassava Sciences appoints new SVP of Clinical Development - Investing.com

Apr 21, 2025
pulisher
Apr 21, 2025

Cassava Announces Retirement of Chief Medical Officer, Dr. - GlobeNewswire

Apr 21, 2025
pulisher
Apr 21, 2025

Cassava Sciences Pivots Beyond Alzheimer's: New Leadership Eyes Breakthrough in Rare Disease Treatment - Stock Titan

Apr 21, 2025
pulisher
Apr 16, 2025

Investigation announced for Long-Term Investors in Cassava - openPR.com

Apr 16, 2025
pulisher
Apr 10, 2025

Cassava Sciences, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsSAVA - ACCESS Newswire

Apr 10, 2025
pulisher
Apr 10, 2025

SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study - MSN

Apr 10, 2025
pulisher
Apr 09, 2025

SAVA Stock Plummets to 52-Week Low at $1.16 Amid Market Struggles By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

SAVA Stock Plummets to 52-Week Low at $1.16 Amid Market Struggles - Investing.com Australia

Apr 09, 2025
pulisher
Apr 07, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire

Apr 07, 2025
pulisher
Apr 05, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cassava Sciences, Inc. (SAVA) And Encourages Stockholders to Connect - ACCESS Newswire

Apr 05, 2025
pulisher
Apr 02, 2025

SAVA stock touches 52-week low at $1.34 amid market challenges By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

SAVA stock touches 52-week low at $1.34 amid market challenges - Investing.com Australia

Apr 02, 2025
pulisher
Apr 02, 2025

SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 01, 2025

Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround - Yahoo Finance

Apr 01, 2025
pulisher
Mar 31, 2025

After Two Phase 3 Trial Fails, Cassava Sciences Gives Up On Alzheimer’s Drugs - Being Patient

Mar 31, 2025
pulisher
Mar 31, 2025

Is the Future Bleak for SAVA Stock Following Another Setback? - Nasdaq

Mar 31, 2025
pulisher
Mar 31, 2025

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug - MSN

Mar 31, 2025
pulisher
Mar 31, 2025

Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful - MSN

Mar 31, 2025
pulisher
Mar 30, 2025

Notable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focus - MSN

Mar 30, 2025
pulisher
Mar 26, 2025

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer’s drug By Reuters - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More - Zacks Investment Research

Mar 26, 2025
pulisher
Mar 26, 2025

Cassava ends Alzheimer’s program after simufilam fails again - The Pharma Letter

Mar 26, 2025
pulisher
Mar 26, 2025

Cassava ends simufilam Alzheimer’s programme after second Phase III failure - Yahoo Finance

Mar 26, 2025

Finanzdaten der Cassava Sciences Inc-Aktie (SAVA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Cassava Sciences Inc-Aktie (SAVA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Schoen Eric
Chief Financial Officer
Nov 29 '24
Option Exercise
1.18
50,000
59,000
71,300
Schoen Eric
Chief Financial Officer
Nov 29 '24
Sale
3.86
59,800
230,828
11,500
Schoen Eric
Chief Financial Officer
Nov 29 '24
Sale
3.82
2,000
7,640
0
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):